Skip to main content
SpringerLink
Log in

Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone

  • Short Communication
  • Mitoxantrone, Mesothelioma, Fibrosis, Chemotherapy
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment. However, laporotomy revealed extensive adhesive fibrosis but no sign of malignant mesothelioma. The peritoneal complications of intraperitoneal cytostatic treatment are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Alberts DS, Chen H-SG, Chang SY, Peng YM (1980) The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. Recent Results Cancer Res 74: 293

    Google Scholar 

  2. Alberts DS, Surwitt EA, Peng Y-M, McCloskey T, Rivest R, Graham V, McDonald L, Roe D (1988) Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res 48: 5874

    Google Scholar 

  3. Antman KH, Pomfret EA, Aisner J, MacIntyre J, Osteen RT, Greenberger JS (1983) Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1: 386

    Google Scholar 

  4. Antman KH, Osteen RT, Klegar KL, Amato DA, Pomfret EA, Larson DA, Corson JM (1985) Early peritoneal mesothelioma: a treatable malignancy. Lancet II: 977

    Google Scholar 

  5. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965–1985. J Clin Oncol 6: 147

    Google Scholar 

  6. Antman KH, Pass HI, Recht A (1989) Benign and malignant mesothelioma. In: DeVita VT, Hellman S, Rosenberg SIA (eds) Cancer, principles and practice in oncology, 3rd edn. J. B. Lippencott, Philadelphia, p 1399

    Google Scholar 

  7. Bergman J-F, Bidart J-M, George M, Beaugrand M, Levy VG, Bohuon C (1987) Elevation of CA 125 in patients with benign and malignant ascites. Cancer 59: 213

    Google Scholar 

  8. Blöchl-Daum B, Eichler HG, Rainer H, Jakesz R, Salzer H, Steger G, Schüller J, Günther E, Proksch B, Ehninger G (1988) Escalating dose regimen of intraperitoneal mitoxantrone: phase I study-clinical and pharmacokinetic evaluation. Eur J Cancer Clin Oncol 24: 1133

    Google Scholar 

  9. Bollinger DJ, Wick MR, Dehner LP, Mills SE, Swanson PE, Clarke RE (1989) Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma — a histochemical and immunohistochemical comparison. Am J Surg Pathol 13: 659

    Google Scholar 

  10. Brenner DE (1986) Intraperitoneal chemotherapy: a review. J Clin Oncol 4: 1135

    Google Scholar 

  11. Eisenhauer EA, Evans WK, Raghavan D, Desmeules MJ, Murray NR, Stuart-Harris R, Wilson KS (1986) Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group study. Cancer Treat Rep 70: 1029

    Google Scholar 

  12. Fountzilas G, Dombros N, Balaskas E, Konstantaras C, Triantafillou A, Kalogera-Fountzila A, Savidis N, Sombolos K, Tourkantonis A (1989) Intraperitoneal chemotherapy with high-dose cisplatin and 5-fluorouracil in patients with advanced ovarian cancer. Reg Cancer Treat 2: 203

    Google Scholar 

  13. Gandhi VC, Humayun HM, Ing TS, Daugirdas JT, Jablokow VR, Iwatsuki S, Geis P, Hano JE (1980) Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 140: 1201

    Google Scholar 

  14. Jones RB, Collins JM, Myers CE, Brooks AE, Hubbard SM, Balow JE, Brennan MF, Dedrick RL, DeVita VT (1981) High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res 41: 55

    Google Scholar 

  15. Litterst CL, Collins JM, Lowe MC, Arnold ST, Powell DM, Guarino AM (1982) Local and systemic toxicity resulting from large-volume ip administration of doxorubicin in the rat. Cancer Treat Rep 66: 157

    Google Scholar 

  16. Marechal F, Berthiot G, Kritly T, Legrand MG, Deltour G, Cattan A (1989) Analysis of CA-125 levels in the sera of patients with non-ovarian carcinomas and non-malignant diseases. Anticancer Res 9: 593

    Google Scholar 

  17. Markman M (1986) Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 13: 219

    Google Scholar 

  18. Markman M, Kelsen D (1989) Intraperitoneal cisplatin and mitomycin as treatment for malignant peritoneal mesothelioma. Reg Cancer Treat 2: 49

    Google Scholar 

  19. Markman M, Cleary S, Howell SB, Lucas WE (1986) Complications of extensive adhesion formation after intraperitoneal chemotherapy. Surg Gynecol Obstet 162: 445

    Google Scholar 

  20. Markman M, George M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL (1990) Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 8: 146

    Google Scholar 

  21. McVie JG, Rodenhuis S, Dubbelman R, Varossiau FJ, Bokkel Huinink WW ten (1987) Clinical pharmacokinetics of intraperitoneal mitoxantrone in ovarian cancer. Proc Am Soc Clin Oncol 6: 41

    Google Scholar 

  22. Monk BJ, Surwit EA, Alberts DS, Graham V (1988) Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery. Semin Oncol 15 [Suppl 4]: 27

    Google Scholar 

  23. Musk AW, Dolin PJ, Armstong BK, Ford JM, Klerk NH de, Hobbs MS (1989) The incidence of malignant mesothelioma in Australia, 1947–1980. Med J Aust 150: 242

    Google Scholar 

  24. Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, Myers CE (1982) Phase I and pharmacological studies of Adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42: 4265

    Google Scholar 

  25. Pfeifle GE, Howell SB, Markman M (1985) Intracavitary cisplatin chemotherapy for mesothelioma. Cancer Treat Rep 69: 205

    Google Scholar 

  26. Plaus W (1988) Peritoneal mesothelioma. Arch Surg 123: 763

    Google Scholar 

  27. Roberts JD, Newman RA, Kimberly PJ, Hacker MP (1986) Regional fibrosis after intraperitoneal administration of mafosfamide. Invest New Drugs 4: 61

    Google Scholar 

  28. Smith IE (1983) Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 10: 103

    Google Scholar 

  29. Sridhar KS, Hussein AM, Feun LG, Zubrod CG (1989) Activity of pirarubicin (4′-0-tetrahydropyranyladriamycin) in malignant mesothelioma. Cancer 63: 1084

    Google Scholar 

  30. Stähelin H (1976) Delayed toxicity of epipodophyllotoxin derivates (VM 26 and VP 16-213) due to local effect. Eur J Cancer 12: 925

    Google Scholar 

  31. Weismann L, Osteen R, Corson J, Herman T, Antman KH (1988) Combined modality therapy for intraperitoneal mesothelioma. Proc Am Soc Clin Oncol 7: 274

    Google Scholar 

  32. Whitley NO, Brenner DE, Antman KH, Grant D, Aisner J (1982) CT of peritoneal mesothelioma: analysis of eight cases. AJR 138: 531

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands

    L. Thomas Vlasveld, Babs G. Taal & Sjoerd Rodenhuis

  2. Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands

    Bin B. R. Kroon

  3. Department of Pathology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands

    Maarten P. W. Gallee

Authors
  1. L. Thomas Vlasveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Babs G. Taal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bin B. R. Kroon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maarten P. W. Gallee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sjoerd Rodenhuis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomas Vlasveld, L., Taal, B.G., Kroon, B.B.R. et al. Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. Cancer Chemother. Pharmacol. 29, 405–408 (1992). https://doi.org/10.1007/BF00686012

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686012

Keywords

Search

Navigation